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Abstract
Objective: To assess the impact of platelet‐rich fibrin (PRF) on implant dentistry. The 
primary focused question was as follows: What are the clinical, histological, and ra‐
diographic outcomes of PRF administration for bone regeneration and implant 
therapy?
Method: A systematic literature search comprised three databases: MEDLINE, 
EMBASE, and Cochrane followed by a hand search of relevant scientific journals. 
Human studies using PRF for bone regeneration and implant therapy were consid‐
ered and articles published up to December 31, 2017 were included. Eligible studies 
were selected based on the inclusion criteria. Randomized controlled trials (RCT) and 
controlled clinical trials (CCT) were included.
Results: In total, 5,963 titles were identified with the search terms and by hand 
search. A total of 12 randomized controlled trials (RCT) met the inclusion criteria and 
were chosen for data extraction. Included studies focused on alveolar ridge preser‐
vation after tooth extraction, osseointegration process, soft tissue management, 
bone augmentation, bone regeneration after sinus floor elevation and surgical peri‐
implantitis treatment. Overall, the risk of bias was moderate or unclear. Nine studies 
showed superior outcomes for PRF for any of the evaluated variables, such as ridge 
dimension, bone regeneration, osseointegration process, soft tissue healing. Three 
studies failed to show any beneficial effects of PRF. No meta‐analysis could be per‐
formed due to the heterogeneity of study designs.
Conclusions: There is moderate evidence supporting the clinical benefit of PRF on 
ridge preservation and in the early phase of osseointegration. It remains unclear 
whether PRF can reduce pain and improve soft tissue healing. More research support 
is necessary to comment on the role of PRF to improve other implant therapy 
outcomes.
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alveolar ridge preservation, guided bone regeneration, implant therapy, platelet‐rich fibrin, 
sinus floor elevation
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1  | INTRODUC TION
Reduced bone height and width are the most common limitations 
for implant placement. To overcome these limitations, guided bone 
regeneration, alveolar ridge preservation, and sinus floor elevation 
were introduced. Even though most of these techniques provide 
predictable outcomes, there is a demand to enhance wound heal‐
ing and bone regeneration either after dental extraction or during 
implant placement. The local application of growth factors and 
scaffolds are supposed to enhance wound healing and bone regen‐
eration. The therapeutic concept is based on the assumption that 
if physiologic concentrations of growth factors are good, a supra‐
physiological concentration of growth factors even better sup‐
ports the early stages of wound healing and bone regeneration. 
However, only few recombinant growth factors are clinically ap‐
proved by the US regulatory agencies (Nevins et al., 2013; Triplett 
et al., 2009). Autologous preparation of growth factors from blood 
usually needs no formal approval. It is nevertheless necessary to 
critically evaluate the safety and efficacy of the various prepara‐
tions of platelets and the respective fibrin‐rich matrix.
Platelet‐rich fibrin (PRF) is prepared from plasma after centrif‐
ugation of whole blood (Choukroun, Adda, Schoeffler & Varvelle, 
2001). Plasma containing platelets and leukocytes undergo sponta‐
neous coagulation. Like in the natural blood clot that forms at the 
defect site, activated platelets and leukocytes are entrapped in the 
fibrin‐rich matrix (Singer & Clark, 1999). PRF can be further pro‐
cessed, for example, by squeezing out further serum resulting in a 
PRF membrane (Dohan et al., 2006) or by mixing with grafts and bio‐
materials as summarized in this and other reviews.
Systematic reviews recently summarized the effects of PRF re‐
lated to implant dentistry. Miron et al. focused on intrabony and 
furcation defects, extraction sockets, sinus lifting, gingival reces‐
sions, and bone augmentation (Miron, Zucchelli, et al., 2017) as 
well as on soft tissue regeneration, augmentation, and/or wound 
healing (Miron, Fujioka‐Kobayashi, et al., 2017). At the same time, 
Castro et al. provided systematic reviews on alveolar ridge pres‐
ervation, sinus floor elevation and implant therapy (Castro et al., 
2017b) as well as intrabony defects, furcation defects, and peri‐
odontal plastic surgery (Castro et al., 2017a). Also, systematic re‐
views on mandibular third molar extractions (Al‐Hamed, Tawfik, 
Abdelfadil, & Al‐Saleh, 2017; Canellas, Ritto, & Medeiros, 2017) 
and gingival recessions (Moraschini & Barboza Edos, 2016) be‐
came available. This study is complementary to these current sys‐
tematic reviews.
2  | MATERIAL AND METHODS
2.1 | Protocol development and eligibility criteria
This review was conducted according to the PRISMA (Preferred 
Reporting Items for Systematic Review and Meta‐Analyses) 
statement, conforming to which a detailed protocol was established 
(Liberati et al., 2009; Moher et al., 2015). The systematic review 
was conducted as the second assessing platelet concentrates and 
implant therapy.
The focused question was formulated based on the PRISMA 
guidelines:
1. Population (P) = humans with lack of alveolar bone and/or 
need of implant therapy or tooth extraction.
2. Intervention (I) = use of PRF alone or in combination with a graft 
material in guided bone regeneration techniques and implant 
therapy.
3. Comparison (C) = respective surgical procedure without PRF.
4. Outcome (O) = alveolar bone regeneration, soft tissue healing, os‐
seointegration, implant stability, graft resorption, periodontal 
probing depth and postoperative life quality issues such as pain.
5. Study design (S) = randomized controlled clinical trials, prospec‐
tive controlled clinical trials, split‐mouth or parallel arms.
The following PICOS question was raised: Is there any additional 
benefit of PRF on guided bone regeneration and implant therapy over 
traditional approaches in terms of clinical, histological and radiographic 
outcomes?
2.2 | Search strategy
An electronic search of three databases (MEDLINE, EMBASE, 
CENTRAL) was performed. Articles published up to December 31, 
2017 were considered. No language or time restrictions were ap‐
plied in the search. However, only studies written in English were 
included for selection. An additional hand search was carried out 
including the bibliographies of the selected papers and other nar‐
rative and systematic reviews as well as in the following journals: 
Clinical Oral Implants Research, Clinical Implant Dentistry and Related 
Research, European Journal of Oral Implantology, Implant Dentistry, 
International Journal of Oral and Maxillofacial Implants, International 
Journal of Periodontics and Restorative Dentistry, Journal of Clinical 
Periodontology, Journal of Dental Research, Clinical Oral Investigations, 
Journal of Oral and Maxillofacial Surgery, Journal of Periodontology, 
Oral Surgery, and Oral Medicine, Oral Radiology, Oral Pathology and 
Endodontics.
2.3 | Search terms
The electronic search strategy included terms related to the inter‐
vention and used the following combination of key words, MeSH and 
Emtree terms: “osseointegration” OR “dental Implants, single‐tooth” 
OR “dental implants” OR “tooth implant” OR “guided bone regenera‐
tion” OR “bone regeneration” OR “alveolar ridge augmentation” OR 
“alveolar bone loss” OR “bone resorption” OR “tooth extraction” OR 
“socket preservation” OR “alveolar process” OR “alveolar ridge pres‐
ervation” OR “sinus floor augmentation” OR “sinus lifting” OR “sinus 
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lift” OR “maxillary sinus” AND “platelet‐rich fibrin” OR “autologous 
platelet concentrate” OR “thrombocyte rich plasma” OR “leukocyte 
platelet‐rich fibrin” OR “pure platelet‐rich fibrin” OR “LPRF” OR “L‐
PRF” OR “advanced platelet‐rich fibrin” OR “APRF” OR “A‐PRF” OR 
“L‐PRF Gel”. Cochrane search filters for RCTs and CCTs were imple‐
mented, with cohort trials also included. The results were limited to 
human studies.
2.4 | Inclusion criteria
1. Randomized clinical trials (RCT) or controlled clinical trials (CCT) 
including at least 10 patients/sites per group.
2. Studies regarding alveolar ridge preservation, soft tissue healing, 
bone augmentation procedures, or implant therapy combined 
with platelet‐rich fibrin.
2.5 | Exclusion criteria
In vitro and preclinical studies, cohort studies, case series, case 
reports, retrospective studies, RCTs or CCTs with less than 10 pa‐
tients/sites per group, and studies not meeting all inclusion criteria.
2.6 | Screening and selection of studies
Publication records and titles identified by the electronic search 
and hand search were independently screened by two reviewers 
(FJS and AS) based on the inclusion criteria. Discrepancies were 
solved by discussion including a third reviewer (RG). Cohen’s Kappa‐
coefficient was used as a measure of agreement between the read‐
ers. Thereafter, full texts of the selected abstracts were obtained. 
Where full texts could not be obtained authors and editors of the 
respective journal were contacted. The two reviewers indepen‐
dently performed the screening process, that is, from the MeSH/
Emtree term search up to the full‐text examination. Then, articles 
that met the inclusion criteria were processed for data extraction.
2.7 | Data extraction and quality assessment
The inclusion criteria were applied for data extraction. The studies 
were classified according to study design and type of intervention. 
Then, outcomes were compiled in tables. All extracted data were 
double‐checked, and any questions that came up during the screen‐
ing and the data extraction were discussed within the authors to aim 
for consensus. Two reviewers (FJS and AS) independently evaluated 
the methodological quality of all included studies using the Cochrane 
Collaboration’s tool for assessing risk of bias in randomized trials 
(Higgins et al., 2011). All included studies were checked for the fol‐
lowing criteria: (a) sequence generation, (b) allocation concealment, 
(c) blinding of participants and personnel, (d) blinding of outcome 
assessment, (e) incomplete outcome data, (f) selective reporting, and 
(g) other bias. Any disagreement was discussed until consensus was 
achieved. Each study was classified into the following groups: low 
risk of bias if all quality criteria were judged as “present,” moderate 
risk of bias if one or more key domains were “unclear,” and high risk 
of bias if one or more key domains were not “present.”
3  | RESULTS
3.1 | Selection of studies
The literature search identified 5,787 potential references in Medline 
and 175 in Embase, of which 37 were eligible after title and abstract 
screening (inter‐reviewer agreement κ=0.95 ± 0.03). Hand search 
identified one more study (Gülsen & Sentürk, 2017). Of the 38 full‐
text articles, 18 did not meet the inclusion criteria and were excluded 
(Figure 1; Table 1 of excluded studies). The remaining 18 RCTs and 2 
CCTs were discussed in the EAO consensus meeting. Studies dealing 
with third molar extractions were excluded (Table 1). In consequence, 
12 RCTs were included for data extraction. The included studies were 
divided into subgroups, depending on the area of PRF application 
(Tables 2‒5):
3.2 | Alveolar bone regeneration (Table 2)
1. Alveolar ridge preservation (Table 2a): n = 3, (Alzahrani, Murriky, 
& Shafik, 2017; Marenzi, Riccitiello, Tia, di Lauro, & Sammartino, 
2015; Temmerman et al., 2016).
2. PRF combined with bone substitutes (Table 2b): n = 1, (Thakkar, 
Deshpande, Dave, & Narayankar, 2016).
3.3 | Implant placement (Table 3)
1. Osseointegration process (Table 3a): n = 3, (Boora, Rathee, & 
Bhoria, 2015; Öncü & Alaaddinoglu, 2015; Tabrizi, Arabion, & 
Karagah, 2017).
2. Soft tissue management (Table 3b): n = 1, (Hehn, Schwenk, 
Striegel, & Schlee, 2016).
3. Horizontal bone augmentation (Table 3c): n = 1, (Angelo, Marcel, 
Andreas, & Izabela, 2015).
3.4 | Sinus floor elevation (Table 4)
Sinus floor elevation (Table 4): n = 2, (Nizam, Eren, Akcali, & Donos, 
2018; Tatullo et al., 2012).
3.5 | Peri-implantitis defects (Table 5)
Peri‐implantitis defects (Table 5): n = 1, (Hamzacebi, Oduncuoglu, 
& Alaaddinoglu, 2015).
3.6 | Exclusion of studies
Exclusion of studies (Table 1) occurred due to insufficient study co‐
hort, missing control group, inappropriate PRF preparation, and ap‐
plication during third molar extraction.
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3.7 | Quality assessment of the included studies
Quality and risk assessment was independently conducted by 
two authors (FJS and AS) and are represented in Figures 2 and 3. 
Discrepancies were solved by discussion until reaching consensus. 
Included RCTs were rated following the Cochrane collaboration’s 
tool for assessing risk of bias. No single study demonstrated low risk 
of bias for all the criteria and the majority of studies showed a mod‐
erate and unclear risk of bias. Most of them provided a detailed re‐
port about randomization but not regarding other key domains such 
as allocation concealment and blinding of the participants, thereby 
increasing the potential risk of bias. Seven studies described the 
randomization process and five the allocation concealment in suf‐
ficient detail. Two of the studies were registered to an online data‐
base, which allows for judgment of selective outcome bias (Öncü & 
Alaaddinoglu, 2015; Tabrizi et al., 2017). No study described an ade‐
quate blinding of patients and personnel. Blinding of outcome asses‐
sors was stated in two trials. Three studies described a sample size 
calculation (Alzahrani et al., 2017; Nizam et al., 2018; Temmerman 
et al., 2016).
F I G U R E  1   PRISMA flow diagram
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3.8 | Study design and evaluation period
A total of four studies were RCTs where a split‐mouth design was 
applied (Marenzi et al., 2015; Nizam et al., 2018; Tabrizi et al., 2017; 
Temmerman et al., 2016). The remaining RCTs used a parallel group 
design. The follow‐up period ranged considerably from 3 weeks to 
12 months.
3.9 | Subject characteristics
All studies included healthy subjects with no active inflammatory 
disease. The mean age varied from 18 to 79. The number of included 
patients lied between 10 and 82. Smokers were included in two, ex‐
cluded in six and not reported in four studies.
3.10 | Data extraction
Included studies presented a high heterogeneity in regards to out‐
come measures, PRF preparation or study duration. Therefore, a 
meta‐analysis was not feasible.
3.11 | Alveolar ridge preservation (totally 72 
patients) (Table 2a)
Two RCTs examined the clinical benefits of PRF in ridge preserva‐
tion, both with positive adjunctive effects. PRF increased radio‐
graphic bone fill at 1, 4, and 8 weeks after tooth extraction and 
reduced alveolar ridge resorption at 4 and 8 weeks (Alzahrani et al., 
2017). Similar findings were reported by Temmerman et al. (2016); 
PRF helped to preserve horizontal and vertical ridge dimensions 
3 months after tooth extraction. Also, postoperative pain was re‐
duced at day 3 and day 5 (Temmerman et al., 2016). Another study 
found pain relief also within the first 3 days and improved soft tissue 
healing (Marenzi et al., 2015).
3.12 | Alveolar ridge preservation combined with 
bone substitutes (totally 36 sites) (Table 2b)
One study looked at the combination of PRF with DFDBA and a col‐
lagen membrane showing that alveolar ridge height was preserved 
to a higher extent (Thakkar et al., 2016).
3.13 | Implant placement: osseointegration process 
(totally 60 patients) (Table 3a)
The included studies examined the impact of PRF on the initial 
osseointegration process all showing an enhanced healing. PRF 
reduced marginal bone loss (Boora et al., 2015). Furthermore, ISQ 
values were increased after 1 and 4 weeks in the PRF group (Öncü 
& Alaaddinoglu, 2015) and after 2, 4, and 6 weeks in the posterior 
maxilla (Tabrizi et al., 2017). Clinical parameters such as probing 
depth and bleeding on probing as well as implant survival did not 
change upon PRF treatment compared to control (Boora et al., 
2015).
3.14 | Implant placement: soft tissue management 
(totally 31 patients) (Table 3b)
Soft tissue augmentation with PRF showed an increased peri‐im‐
plant tissue loss compared to control (Hehn et al., 2016) that was 
attributed to the slightly different flap design in the test group.
3.15 | Implant placement: horizontal bone 
augmentation (totally 82 patients) (Table 3c)
PRF was unable to influence the insertion torque when PRF was 
combined with β‐TCP (Angelo et al., 2015).
3.16 | Sinus floor elevation (totally 73 patients) 
(Table 4)
PRF increased the amount of medullary spaces and osteoid borders 
(Tatullo et al., 2012). PRF showed no beneficial effects on neither 
new bone formation, bone height gain, soft tissue, and resorption of 
TA B L E  1   List of excluded full‐text papers and reasons for 
exclusion following full‐text screening
Author and year Reasons for exclusion
Afat et al. (2017) Third molars
Agarwal et al. (2015) Intrabony defects
Baslarli et al. (2015) Third molars
Bolukbasi et al. (2013) No control group
Choukroun et al. (2006) Insufficient number of patients
Cömert‐Kilic et al. (2017) Insufficient number of patients
Das et al. (2016) PRF being not the only variable
Du Toit et al. (2016) Insufficient number of patients
Dutta et al. (2016) Not appropriate PRF protocol
Gürbüzer et al. (2010) Third molars
Gülsen et al. (2017) Third molars
Hauser et al. (2013) Insufficient number of patients
Huang et al. (2016) Case report
Khan et al. (2017) PRF protocol
Kumar et al. (2014) Third molars
Mazor et al. (2009) No control group
Moussa et al. (2016) Insufficient number of patients
Ozgul et al. (2015) Third molars
Shah et al. (2017) Case report
Singh et al. (2012) Third molars
Taschieri et al. (2011) No control group
Toffler et al. (2010) No control group
Varghese et al. (2017) Third molars
Yelamali et al. (2015) No control group
Zhang et al. (2012) Insufficient number of patients
Zhao et al. (2015) No control group
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DBBM (Nizam et al., 2018) nor on the implant survival at 12 (Nizam 
et al., 2018) and 36‐month follow‐up (Tatullo et al., 2012).
3.17 | Peri-implantitis defects (totally 19 patients) 
(Table 5)
One study assessed the clinical outcome of open flap debridement 
with and without PRF. PRF increased the probing depth reduction, 
increased the gain in clinical attachment and reduced mucosal reces‐
sion after 3 and 6 months (Hamzacebi et al., 2015).
4  | DISCUSSION
The present systematic review focused on RCTs using PRF in all 
fields of implant dentistry including alveolar ridge preservation and/
or augmentation, implant placement, sinus floor augmentation, and 
peri‐implantitis. The aim was to evaluate the current literature with 
respect to the clinical indications for PRF in bone regeneration and 
in soft tissue healing in respect to implant therapy. The selected 
publications revealed a great heterogeneity with a general lack of 
conclusive evidence, in large part due to low power and incomplete 
reporting of the study design. Owing to the heterogeneity of the 
studies no meta‐analysis could be performed.
4.1 | Alveolar bone regeneration
The main goal of alveolar ridge preservation is to preserve the 
hard and soft tissue following tooth extraction and to facilitate 
implant placement in a prosthetically driven position. Two stud‐
ies evaluated the dimensional changes of the alveolar process 
using L‐PRF only (Alzahrani et al., 2017; Temmerman et al., 2016). 
Both studies concluded that PRF reduces alveolar width resorp‐
tion from 8 weeks to up to 6 months postoperatively. Both stud‐
ies used more than one L‐PRF clot or membrane: Alzahrani et al. 
inserted 2 membranes and Temmerman et al. inserted 3–7 mem‐
branes. The number of clots or membranes within a site and the 
respective blood volume might affect the clinical outcome (Castro 
et al., 2017b). In consequence, the number of membranes/clots 
might modulate the cellular microenvironment in the socket.
One study assessed ridge preservation using the combination 
of L‐PRF with demineralized freeze‐dried bone allografts (DFDBA) 
(Thakkar et al., 2016). In the PRF group, the ridge width demon‐
strated fewer dimensional changes over 180 days. However, 
Thakkar et al. cannot be compared with the aforementioned stud‐
ies as here a grafting material was used. Moreover, they utilized 
only one clot compared to the multiple clots/membranes used by 
others (Alzahrani et al., 2017; Marenzi et al., 2015; Temmerman 
et al., 2016). Marenzi et al. reported an improvement in soft tissue 
healing after 7, 14, and 21 days; however, the clinical interpreta‐
tion is challenging due to the plethora of healing indexes in the 
literature. Moreover, based on a single study it is difficult to draw 
a strong conclusion. Another relevant aspect that requires further TA
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attention is the regenerative potential of L‐PRF on different bio‐
types that is not reported in either of the studies. There is also 
a general lack of patient characteristics that can influence bone 
resorption.
4.2 | Implant placement
Five studies were included with respect to PRF application during 
implant placement. Two RCTs assessed the impact of PRF prior to 
implant insertion (Öncü & Alaaddinoglu, 2015; Tabrizi et al., 2017). 
Higher ISQ values were detected in the test group compared to 
noncoated implants. This implies that PRF might enhance implant 
stability during the early phase of osseointegration. Another 
study showed less marginal bone loss with PRF (Boora et al., 
2015). However, this data is limited to implants with a follow‐up 
of 3 months. Furthermore, no effects on bone loss were observed 
when a PRF membrane was placed over the implant (Hehn et al., 
2016). There was even a decrease in mucosa thickness after 
3 months in the PRF group, and the study was terminated after 10 
cases (Hehn et al., 2016). Overall, due to the heterogeneity of the 
F I G U R E  2   Quality assessment of the included studies: Risk of 
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outcome measures, it is difficult to draw a conclusion from PRF 
during implant placement. This is also true for implant placement 
combined with horizontal bone augmentation (Angelo et al., 2015) 
where PRF failed to affect insertion torque.
4.3 | Sinus floor elevation
Sinus floor elevation procedures are highly effective yet not free of 
complications. Complications associated with sinus floor elevation 
include graft resorption, membrane perforation, or sinusitis. Two 
studies met the inclusion criteria (Nizam et al., 2018; Tatullo et al., 
2012). Implant survival rate was 100% after a one (Nizam et al., 
2018) and 3‐year (Tatullo et al., 2012) follow‐up, regardless of PRF. 
These two studies combined PRF with DBBM. No RCT could be 
identified where PRF was used as the sole filling material or in com‐
bination with autologous bone. In addition, PRF did not change bone 
formation, soft tissue area, resorption of residual bone grafts, and 
the augmented bone height (Nizam et al., 2018). The studies did not 
report on membrane perforations and sinusitis, precluding any con‐
clusion about its potential benefit in the management of complica‐
tions. Although in vitro and preclinical data (Miron, Zucchelli, et al., 
2017) encourage the use of PRF in sinus floor elevation, the clinical 
evidence gathered so far does not support its use. Moreover, neither 
of the two studies assessed patient‐reported outcomes.
In summary, inconclusive results are reported on PRF in sinus floor 
elevation procedures whereby a lack of well‐designed studies with ap‐
propriate endpoints are needed. Therefore, the effect of PRF on bone 
regeneration during sinus floor elevation remains questionable.
4.4 | PRF and pain
Pain is a relevant patient‐reported outcome measure (Coulthard, 
Patel, Bailey, & Coulthard, 2014). Two studies reported patient‐re‐
ported outcomes measured using the visual analog scale (Marenzi 
et al., 2015; Temmerman et al., 2016). Temmerman et al. (2016) 
concluded that PRF significantly reduced pain sensations after 3 
to 5 days and Marenzi et al. (2015) noted significantly less pain in 
the PRF group up to the 21st day. Nevertheless, it has to be taken 
into account that both studies did not state whether the patients 
were adequately blinded. There are numerous studies assessing PRF 
effect on pain with mandibular third molar extraction (Al‐Hamed 
et al., 2017). However, only few studies used a blinded protocol 
(Afat, Akdogan, & Gonul, 2017; Ozgul et al., 2015). In consequence, 
patient‐reported outcomes such as pain must be interpreted with 
caution.
4.5 | Peri-implantitis
Peri‐implantitis requires new approaches and techniques to be es‐
tablished. One approach might be the use of PRF. Only one RCT, 
with a 6‐month follow‐up, observed the effect of PRF in peri‐im‐
plantitis defects (Hamzacebi et al., 2015). Although a significant 
improvement of pocket reduction, clinical attachment gain, and 
mucosal recession was found in the PRF group, it is not possible 
to draw a definitive conclusion. The defects were insufficiently 
described in their anatomy. Whether PRF is effective in peri‐im‐
plantitis defects remains to be investigated with further well‐de‐
signed RCTs.
5  | CONCLUSION
Based on studies with a rather limited statistical power, the pre‐
sent systematic review suggests that (i) PRF might reduce alveolar 
width resorption, and might enhance implant stability during the 
early phase of osseointegration. (ii) PRF combined with grafting 
materials has no effect in sinus floor elevation, and, (iii) there is 
a lack of adequate studies for implant placement, peri‐implantitis 
defects, soft tissue healing, and postoperative pain, although the 
preliminary data seems promising.
6  | FUTURE DIREC TION
The studies included in this review mainly focused on surrogate 
parameters to evaluate the effect of PRF. The clinical relevance of 
the outcome measurements remains questionable. Even though 
it is possible to use PRF in almost every procedure in implant 
dentistry, its potential clinical benefit on the long‐term outcomes 
has not yet been established. A low number of studies report on 
F I G U R E  3   Quality assessment of the 
included studies: Risk of bias graph
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implant placement and peri‐implantitis. With regards to sinus 
floor elevation, RCTs investigating PRF as the sole filling material 
or in combination with autologous bone need to be carried out. 
Another interesting aspect that requires further attention is to 
investigate possible effects of PRF in medically compromised pa‐
tients or in extraction sockets with severe buccal bone deficiency. 
It needs to be evaluated in which clinical situations and for what 
patient group PRF is most effective. In addition, the number of 
PRF membranes to obtain a clinical benefit still remains unclear. 
Further well‐designed RCTs are necessary to state, in which clini‐
cal indication and for what kind of patients the use of PRF can be 
recommended.
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